OR WAIT null SECS
Industry Standard Research (ISR) announced the release of two new reports focused on the Biosimilar industry. “US Payers and Biosimilar Formulary Placement” and “Biosimilars: A View from the Pharmacy” expand the base of knowledge regarding Biosimilar market dynamics. These reports look at how these two segments of the healthcare delivery system view, among other things, Biosimilar pricing, formulary placement, pharmacy-level substitution, and clinical trial requirements.
“This is our third installment in our Biosimilar Primer series. We are starting to see physicians, pharmacists, and payers having very different views on how they see the landscape of Biosimilars unfolding.” explained Andrew Schafer, President of Industry Standard Research.
One interesting data point from the “US Payers and Biosimilar Formulary Placement” report is that while very few payer organizations have a separate formulary tier for Biosimilars today, in two years the adoption of a separate tier is expected to climb substantially.
These reports provide pharmaceutical companies, contract research organizations, marketing, and consulting companies with baseline views of how these constituents view some major topics relating to Biosimilars. The data contained in all three of ISR’s Biosimilar Primer series can be used as foundational elements for an organization’s strategic planning around Biosimilars.
“The Biosimilar market is one that is obviously heating up. We have seen several recent announcements around development programs and/ or partnerships designed to develop and commercialize Biosimilars. ISR will continue to monitor this industry and we are planning a Patient Recruitment in Biosimilar Trials report later this year to help round out our subscriber’s knowledge base.”